IntelGenx Tech Corp (fka IGXT)

[stockjuicer]

We'll said!!!

I jumped in at 0.76, I need to find more DD on this to stay in past 1.25, any good sources (articles etc) you can refer to me so that I can read?

All I could find is the following from an earlier post (worth reading)

------

IGXT is one of the Best and Most Undervalued Gem in the Biotech Sector . Market Cap of $48 M for a Company with10 Drugs in Late Stage which all could be on the Market within 3 years is more than Ridiculous .

2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .

NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)

IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)

Only 35 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

Intelgenx (IGXT)

Market Cap : $62 M
Cash: $6 M
Price:0.96

Burn-Rate : $2 M a year
Shares Out : 69 M ( 31 M shares are held by Investors )

IGXT Monster Pipeline :

Product Application Status of Development

Forfivo Antidepressant---- US launch in 4Q 2012

INT0008 Anti-Migraine--PDUFA DATE on February 3

INT0027 Opoid Dependence -- ANDA under review by FDA (Partnered with Par Pharma)

INT0007 Erectile Dysfunction -- NDA filing early 2014

INT0001 CHF (Coronary Heart Failure), Hypertension -- ANDA filing early 2014

INT0036 Insomnia -- in Pivotal Study

INT0024 Idiopathic pulmonary fibrosis -- in Pivotal Study

INT0027 Cancer pain (cannabinoid) --in Pivotal Study

INT0030 Animal health -- in Pivotal Study

INT0035 Benign prostatic hyperplasia --in Pivotal Study Less